Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer
- PMID: 16264989
- DOI: 10.1038/ncponc0195
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer
Abstract
Members of the signal transducers and activators of transcription (STAT) pathway, which were originally identified as key components linking cytokine signals to transcriptional events in cells, have recently been demonstrated to have a major role in cancer. They are cytoplasmic proteins that form functional dimers with each other when activated by tyrosine phosphorylation. Activated STAT proteins translocate to the nucleus to regulate expression of genes by binding to specific elements within gene promoters. Constitutive activation of the STAT family members Stat3 and Stat5, and/or loss of Stat1 signaling, is found in a large group of diverse tumors. Increasing evidence demonstrates that STAT proteins can regulate many pathways important in oncogenesis including cell-cycle progression, apoptosis, tumor angiogenesis, tumor-cell invasion and metastasis, and tumor-cell evasion of the immune system. Based on these findings, a growing effort is underway to target STAT proteins directly and indirectly for cancer therapy. This review will highlight STAT signaling pathways, STAT target genes involved in cancer, evidence for STAT activation in human cancers, and therapeutic strategies to target STAT molecules for anticancer therapy.
Similar articles
-
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.Clin Cancer Res. 2002 Apr;8(4):945-54. Clin Cancer Res. 2002. PMID: 11948098 Review.
-
The role of STATs in transcriptional control and their impact on cellular function.Oncogene. 2000 May 15;19(21):2468-73. doi: 10.1038/sj.onc.1203476. Oncogene. 2000. PMID: 10851045 Review.
-
STAT proteins: from normal control of cellular events to tumorigenesis.J Cell Physiol. 2003 Nov;197(2):157-68. doi: 10.1002/jcp.10364. J Cell Physiol. 2003. PMID: 14502555 Review.
-
STAT proteins: novel molecular targets for cancer drug discovery.Oncogene. 2000 Dec 27;19(56):6613-26. doi: 10.1038/sj.onc.1204086. Oncogene. 2000. PMID: 11426647 Review.
-
STATs in oncogenesis.Oncogene. 2000 May 15;19(21):2474-88. doi: 10.1038/sj.onc.1203527. Oncogene. 2000. PMID: 10851046 Review.
Cited by
-
The Prowess of Andrographolide as a Natural Weapon in the War against Cancer.Cancers (Basel). 2020 Aug 4;12(8):2159. doi: 10.3390/cancers12082159. Cancers (Basel). 2020. PMID: 32759728 Free PMC article. Review.
-
A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability.PLoS Comput Biol. 2012;8(2):e1002370. doi: 10.1371/journal.pcbi.1002370. Epub 2012 Feb 16. PLoS Comput Biol. 2012. PMID: 22359489 Free PMC article.
-
Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo.Oncogene. 2013 May 9;32(19):2433-41. doi: 10.1038/onc.2012.260. Epub 2012 Jul 2. Oncogene. 2013. PMID: 22751114 Free PMC article.
-
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.Genes Cancer. 2012 Jul;3(7-8):503-11. doi: 10.1177/1947601912466555. Genes Cancer. 2012. PMID: 23264850 Free PMC article.
-
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5. J Immunother Cancer. 2018. PMID: 30446007 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous